X4 Pharmaceuticals, Inc.
NASDAQ: XFOR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adam R. Craig
- Employees
- 143
- Headquarters
- Boston, United States
- IPO year
- 2017
- Market cap
- $385.8M
- Website
- https://www.x4pharma.com
Loading XFOR…
Loading profile data…Frequently asked questions about XFOR
What does X4 Pharmaceuticals, Inc. (XFOR) do?
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine rece...
Where does XFOR trade?
X4 Pharmaceuticals, Inc. (XFOR) trades on the NASDAQ Capital Market.
What sector is XFOR in?
X4 Pharmaceuticals, Inc. (XFOR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of X4 Pharmaceuticals, Inc.?
Adam R. Craig is the chief executive officer of X4 Pharmaceuticals, Inc. (XFOR).
Where is X4 Pharmaceuticals, Inc. headquartered?
X4 Pharmaceuticals, Inc. is headquartered in United States.
Does XFOR pay a dividend?
X4 Pharmaceuticals, Inc. (XFOR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XFOR go public?
X4 Pharmaceuticals, Inc. (XFOR) completed its initial public offering in 2017.